Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Clene Inc (CLNN)

Clene Inc (CLNN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,446
  • Shares Outstanding, K 8,983
  • Annual Sales, $ 340 K
  • Annual Income, $ -39,400 K
  • EBIT $ -28 M
  • EBITDA $ -26 M
  • 60-Month Beta 0.49
  • Price/Sales 112.42
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.48
  • Number of Estimates 2
  • High Estimate -0.39
  • Low Estimate -0.58
  • Prior Year -1.06
  • Growth Rate Est. (year over year) +54.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.28 +87.71%
on 05/23/25
4.95 -13.54%
on 06/02/25
+1.68 (+64.62%)
since 05/20/25
3-Month
2.28 +87.71%
on 05/23/25
4.95 -13.54%
on 06/02/25
+0.01 (+0.23%)
since 03/20/25
52-Week
2.28 +87.71%
on 05/23/25
8.20 -47.80%
on 06/21/24
-3.54 (-45.30%)
since 06/20/24

Most Recent Stories

More News
Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

CLNN : 4.28 (-2.06%)
Clene to Present at the Emerging Growth Conference

CLNN : 4.28 (-2.06%)
Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session

CLNN : 4.28 (-2.06%)
Clene (NASDAQ: CLNN) to Present at Jones Healthcare and Technology Innovation Conference

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases like ALS and MS, will present at the Jones Healthcare and Technology Innovation...

CLNN : 4.28 (-2.06%)
Clene to Present at the Jones Healthcare and Technology Innovation Conference

CLNN : 4.28 (-2.06%)
Clene’s (NASDAQ: CLNN) Q1 Virtual Investor Summit Available for On-Demand Viewing

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function...

CLNN : 4.28 (-2.06%)
Clene (NASDAQ: CLNN) Plans 2025 NDA Submission Following Positive ALS Trial Data

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, reported a full-year 2024 net loss of $39.4 million, or $5.67 per share, compared to a loss of $49.5 million in 2023. Revenue remained...

CLNN : 4.28 (-2.06%)
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

CLNN : 4.28 (-2.06%)
Clene’s (NASDAQ: CLNN) CNM-Au8(R) Delivers Significant Survival Benefits in New Analyses of Healey ALS Platform Trial Data

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function...

CLNN : 4.28 (-2.06%)
Q1 Virtual Investor Summit: On-Demand Presentations Now Live

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors...

SNANF : 0.3085 (+3.18%)
BRNS : 0.8411 (-3.32%)
FEMY : 0.8500 (-3.41%)
PERF : 2.01 (-0.50%)
DRTS : 2.90 (-0.35%)
GIFT : 1.4900 (+21.14%)
ROYIF : 0.0642 (+163.11%)
ZCAR : 0.5950 (-12.50%)
CLNN : 4.28 (-2.06%)
MIND : 6.59 (+10.20%)
PYPD : 3.28 (-0.91%)
TOVX : 0.4323 (-4.15%)

Business Summary

Clene Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of unique therapeutics for neurodegenerative diseases. Clene Nanomedicine Inc., formerly known as Tottenham Acquisition I Limited, is based in SALT LAKE CITY.

See More

Key Turning Points

3rd Resistance Point 4.57
2nd Resistance Point 4.49
1st Resistance Point 4.38
Last Price 4.28
1st Support Level 4.19
2nd Support Level 4.11
3rd Support Level 4.00

See More

52-Week High 8.20
Fibonacci 61.8% 5.94
Fibonacci 50% 5.24
Fibonacci 38.2% 4.54
Last Price 4.28
52-Week Low 2.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »